2017 ESMO Meeting Highlights in Pancreatic Cancer

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: October 31, 2017
Expiration Date: October 31, 2018

Expected time to complete this activity as designed: 45 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

Pancreatic cancer has now moved from the fourth leading cause of cancer-related death in the United States to the third, surpassing breast cancer. It is one of the few cancers where mortality is increasing, and most recent statistics show the 5-year overall survival rate for patients diagnosed with pancreatic cancer is just 8%. Although these statistics are illustrative of a poor prognosis, recent advances in pancreatic cancer treatment options hold promise in improving outcomes for patients.

In this activity, participants will hear from leading experts in pancreatic cancer as they provide a review of key abstracts presented this year at the European Society of Medical Oncology (ESMO) conference held in Madrid Spain.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in pancreatic cancer.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Summarize the efficacy and safety data from clinical trials investigating novel therapies and treatment strategies in patients with pancreatic cancer
  • Describe expert faculty perspectives on key clinical trial data for novel therapies and treatment strategies in pancreatic cancer
  • Recognize the potential impact of clinical trials on clinical practice and existing treatment paradigms in pancreatic cancer


Multiple randomized phase 2 studies of PEGPH20 in patients with untreated mPDA and the treatment and management of musculoskeletal events with PEGPH20 – Andrea J. Bullock, MD, MPH

Overall survival and immunologic responses in mPDAC on PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX) – J. Randolph Hecht, MD

Interim efficacy and safety results from the Phase 2 LAPACT trial and health-related quality of life – Philip A. Philip, MD, FRCP

Instructions for Participation and Credit

This activity is eligible for credit through October 31, 2018. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Andrea J. Bullock, MD, MPH
Instructor in Medicine
Department of Internal Medicine
Division of Hematology-Oncology
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Dr. Andrea Bullock received her medical degree from Washington University School of Medicine in St. Louis, Missouri, and her MPH from Harvard University School of Public Health. She completed her internal medicine internship and residency, as well as a hematology-oncology fellowship at Beth Israel Deaconess Medical Center. Dr. Bullock is a physician and an instructor in Medicine, Department of Internal Medicine, Division of Hematology-Oncology, at Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Dr. Bullock holds American Board of Internal Medicine certification in hematology and medical oncology. She is a founding member of the Pancreatic Cancer Center at Beth Deaconess Medical Center and a member of the national Pancreatic Cancer Research Team network. She is also a founding member of the multidisciplinary Liver Tumor Clinic. In addition, she is a member of the American Medical Women’s Association, American Medical Association, Massachusetts Medical Society, and the American Society of Clinical Oncology. Dr. Bullock is the hematology and oncology section editor, and associate editor special topics in oncology for Clinical Therapeutics. She is also an ad hoc reviewer for Cancer, Clinical Therapeutics, Cancer Medicine, Frontline Gastroenterology, and Case Reports in Medicine. Her research efforts focus on improving understanding of cancer pathogenesis and developing rationally resigned therapeutic strategies to address the needs of patients with gastrointestinal cancers, particularly pancreatic cancer.

J. Randolph Hecht, MD
Professor of Clinical Medicine
David Geffen School of Medicine at UCLA
Director, UCLA Gastrointestinal Oncology Program
Los Angeles, California

Dr. J. Randolph Hecht received his medical degree from Eastern Virginia Medical School. He completed his internal medicine residency at Northwestern, followed by fellowships in gastroenterology research at the University of Chicago and in gastroenterology and medical oncology at UCLA. Dr. Hecht is a Professor of Clinical Medicine in the David Geffen School of Medicine at UCLA School of Medicine. He holds the Carol and Saul Rosenzweig Chair for Cancer Therapies Development and is the Director of the UCLA Gastrointestinal Oncology Program.

Dr. Hecht is an internationally known clinical and translational researcher in the field of gastrointestinal cancers. He has published widely on the molecular biology, early detection, and treatment of gastrointestinal malignancies. He has lead and is currently directing small trials with new molecules as well as large international randomized trials. Current ongoing research includes preclinical models of therapy with biological agents, early studies with gene therapy vectors and tyrosine kinase inhibitors, and leading phase II and phase III trials with novel agents.

Philip A. Philip, MD, PhD, FRCP, FABC
Professor of Oncology, Pharmacology and Medicine
Kathryn Cramer Endowed Chair in Cancer Research
Vice President of Medical Affairs
Department of Oncology
Karmanos Cancer Institute
Wayne State University School of Medicine
Detroit, Michigan

Dr. Philip Philip received his medical degree from the University of Baghdad, College of Medicine in Iraq, and his PhD in clinical pharmacology and pharmacogenetics at the University of London Guy’s Hospital Medical School in the UK. He completed a residency at the University of Baghdad, and a fellowship in medical oncology at the University of Oxford and the MD Anderson Cancer Center in Houston, Texas. Dr. Philip is Professor of Oncology, Pharmacology and Medicine, the Endowed Dr. Kathryn Cramer Professor of Cancer Research, as well as Vice President of Medical Affairs at the Karmanos Cancer Institute at Wayne State University School of Medicine in Detroit.

Dr. Philip is USA board-certified in medical oncology and is a fellow of the Royal College of Physicians in the UK. He is leader of hepatopancreatic biliary track, a member of planning committee of ASCO GI 2017, and chairs the pancreatic cancer committee at the Southwest Oncology Group (SWOG). In addition, he holds membership in the International Liver Cancer Association, American Pancreatic Association, American Society of Clinical Oncology, American Association for Cancer Research, and the Pharmacology and Molecular Mechanisms Group (PAMM) of the EORTC, among others.

A frequent national and international lecturer, Dr. Philip authored more than 200 manuscripts, review articles, editorials, and co-edited a book on pancreatic cancer. His major research interests are in the development of new therapies for gastrointestinal and neuroendocrine cancers with a special focus on pancreatic cancer. He has been the principal investigator on numerous local and national clinical trials in GI cancers.


Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.75 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-17-175-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Andrea Bullock has received honoraria related to formal advisory activities from Bayer AG and Celgene Corporation, as well as consultant fees from Halozyme, Inc.

Dr. J. Randolph Hecht has received consultant fees as well as grant support related to research activities from ARMO Biosciences.

Dr. Philip Philip has received honoraria as a consultant from Celgene Corporation, Cornerstone Therapeutics Inc., Eli Lilly and Company, Halozyme, Inc., Lexicon Pharmaceuticals, Inc., Merck & Co., Inc., and Merrimack Pharmaceuticals, Inc., as well as speakers’ bureau activities from Amgen Inc., Celgene, and Eli Lilly. He has received grant support related to research activities from Bayer AG, Celgene, Eli Lilly, Gilead, Halozyme, Merck, and Novartis.

Planning Committee Disclosures

The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation

©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.